期刊
IMMUNOTHERAPY
卷 1, 期 2, 页码 289-302出版社
FUTURE MEDICINE LTD
DOI: 10.2217/1750743X.1.2.289
关键词
cancer; clinical study; dendritic cell; immunogenicity; immunotherapy; tolerance
类别
资金
- Institut national de la sante et de la recherche medicale (INSERM)
- Association pour la Recherche contre le Cancer (ARC)
Much effort has been made over the last decade to use dendritic cells (DCs) in vaccines to induce specific antitumor immune responses. However, the great hope provided by in vitro and in vivo preclinical investigations was not translated to the clinic in terms of clinical efficacy. Thus, one of the challenges resides in optimizing DC-based therapy to give maximum clinical efficacy while using manufacturing processes that enable quality control and scale-up of consistent products. In this article, we review DC biology and the DC-based clinical trials performed to date and focus on the DC maturation status compatible with the goals of cancer immunotherapy. We also highlight the different approaches used in these clinical studies, such as the DC types or subtypes used and their preparation. Finally, we discuss the immunological and clinical outcomes in treated patients, with emphasis on the strategies that could be used to improve DC-based vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据